Figure 2
From: Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine
The SP in human PDAC is resistant to gemcitabine as analyzed in vivo.(A) SCID mice with corresponding PDAC xenograft tumours treated with vehicle (control or Co, left) or gemcitabine (GEM, right). Tumours measured 276 mm3 and 266 mm3 in the control mouse and 144 mm3 and 123 mm3 in the GEM-treated mouse, respectively. (B) Overview of the data, indicating PDAC xenograft number, percent change in tumour volume after treatment with vehicle (Co) or GEM (response to GEM when >50% reduction), and proportion of SP in the tumours after treatment. (C) Boxplot of SP proportion in the PDAC xenografts of the vehicle-treated control mice (Co) and the mice treated with GEM (n = 7). *, p < 0.05.